In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AB Science completes €20.6mm IPO on NYSE Euronext

Executive Summary

AB Science (protein kinase inhibitor therapeutics) has listed on the NYSE Euronext in a €20.6mm ($27.5mm) IPO of 1.6mm shares (including the over-allotment) priced at €12.65, making it one France's first biopharmas to go public since 2007. Incidentally, another French biotech completed an IPO this month as well: immunotherapeutics firm NeoVacs SA (€10mm).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies